United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - nepafenac 3 mg in 1 ml - ilevro* 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ilevro* 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (nsaids). teratogenic effects. pregnancy category c: reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. at this dose, the animal plasma exposure to nepafenac and amfenac was approximately 70 and 630 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 20 and 180 times human plasma exposure for rabbits, respectively. in rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival. nepafenac has been shown to cro

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - nepafenac 1 mg in 1 ml - nevanac® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. nevanac 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (nsaids). teratogenic effects pregnancy category c: reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. at this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. in rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased post-implantation loss, reduced fetal weights and growth, and reduced fetal survival. nepafenac has been shown to cross

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - nepafenac 1 mg in 1 ml - nevanac® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. nevanac® is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nsaids. enter section text here teratogenic effects. pregnancy category c: reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. at this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. in rats, maternally toxic doses ≥ 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival. nepafenac has been shown to cross the placent

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - nepafenac 9.9 g in 10 g

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - nepafenac, quantity: 3 mg/ml - eye drops, suspension - excipient ingredients: carbomer 974p; carmellose sodium; benzalkonium chloride; boric acid; sodium hydroxide; hydrochloric acid; sodium chloride; propylene glycol; guar galactomannan; purified water; disodium edetate - ilevro is indicated for the:,- prevention and treatment of postoperative pain and inflammation associated with cataract surgery,- reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - 1 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - nepafenac, quantity: 3 mg/ml - eye drops, suspension - excipient ingredients: carbomer 974p; carmellose sodium; benzalkonium chloride; boric acid; sodium hydroxide; hydrochloric acid; sodium chloride; propylene glycol; guar galactomannan; purified water; disodium edetate - ilevro is indicated for the:,- prevention and treatment of postoperative pain and inflammation associated with cataract surgery,- reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - ilevro® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ilevro® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (nsaids). teratogenic effects. pregnancy category c: reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. at this dose, the animal plasma exposure to nepafenac and amfenac was approximately 70 and 630 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 20 and 180 times human plasma exposure for rabbits, respectively. in rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival. nepafenac has been shown to cross the

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - nepafenac (unii: 0j9l7j6v8c) (nepafenac - unii:0j9l7j6v8c) - nevanac® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery. nevanac 0.1% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (nsaids). teratogenic effects pregnancy category c: reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. at this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. in rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased post-implantation loss, reduced fetal weights and growth, and reduced fetal survival. nepafenac has been shown to cross

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - nepafenac -